Physiological functions of TNF family receptor/ligand interactions in hematopoiesis and transplantation

Blood

Volumn 124, Issue 2, 2014, Pages 176-183

  Mizrahi, Keren ^a   Askenasy, Nadir ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; BONE MARROW; BONE MARROW TRANSPLANTATION; CELL DEATH; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CHEMORADIOTHERAPY; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNITY; IMMUNOREGULATION; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOMATIC CELL; SPECIES DIFFERENCE; TISSUE INJURY; TISSUE REGENERATION; UMBILICAL CORD BLOOD; UPREGULATION;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LIGANDS; MULTIGENE FAMILY; PROTEIN BINDING; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904131458     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-03-559641     Document Type: Review

References (107)

1. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3(9):745-756. (Pubitemid 41070815)
2. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004;6(3):203-208.
3. Greil R, Anether G, Johrer K, Tinhofer I. Tuning the rheostat of the myelopoietic system via Fas and TRAIL. Crit Rev Immunol. 2003;23(4): 301-322. (Pubitemid 37549552)
4. Testa U. Apoptotic mechanisms in the control of erythropoiesis. Leukemia. 2004;18(7): 1176-1199. (Pubitemid 39023128)
5. Traver D, Akashi K, Weissman IL, Lagasse E. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity. 1998;9(1):47-57. (Pubitemid 28361294)
6. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119(3):651-665.
7. Broxmeyer HE, Williams DE, Lu L, et al. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. J Immunol. 1986; 136(12):4487-4495. (Pubitemid 16090666)
8. Wisniewski D, Strife A, Atzpodien J, Clarkson BD. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia. Cancer Res. 1987;47(18):4788-4794. (Pubitemid 17143020)
9. Vinci G, Chouaib S, Autran B, Vernant JP. Evidence that residual host cells surviving the conditioning regimen to allogeneic bone marrow transplantation inhibit donor hematopoiesis in vitro - the role of TNF-alpha. Transplantation. 1991;52(3):406-411.
10. Saheki K, Fujimori Y, Takemoto Y, Kakishita E. Increased expression of Fas (APO-1, CD95) on CD34+ haematopoietic progenitor cells after allogeneic bone marrow transplantation. Br J Haematol. 2000;109(2):447-452. (Pubitemid 30350733)
11. Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 1995;85(11):3183-3190.
12. Nagafuji K, Shibuya T, Harada M, et al. Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood. 1995; 86(3):883-889.
13. Selleri C, Sato T, Anderson S, Young NS, Maciejewski JP. Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol. 1995; 165(3):538-546.
14. Backx B, Broeders L, Bot FJ, Löwenberg B. Positive and negative effects of tumor necrosis factor on colony growth from highly purified normal marrow progenitors. Leukemia. 1991; 5(1):66-70.
15. Caux C, Favre C, Saeland S, et al. Potentiation of early hematopoiesis by tumor necrosis factor-alpha is followed by inhibition of granulopoietic differentiation and proliferation. Blood. 1991; 78(3):635-644.
16. Rusten LS, Jacobsen FW, Lesslauer W, Loetscher H, Smeland EB, Jacobsen SE. Bifunctional effects of tumor necrosis factor alpha (TNF alpha) on the growth of mature and primitive human hematopoietic progenitor cells: involvement of p55 and p75 TNF receptors. Blood. 1994;83(11):3152-3159. (Pubitemid 24158459)
17. Jacobsen FW, Veiby OP, Stokke T, Jacobsen SE. TNF-alpha bidirectionally modulates the viability of primitive murine hematopoietic progenitor cells in vitro. J Immunol. 1996;157(3): 1193-1199.
18. Ploemacher RE, van Os R, van Beurden CA, Down JD. Murine haemopoietic stem cells with long-term engraftment and marrow repopulating ability are more resistant to gamma-radiation than are spleen colony forming cells. Int J Radiat Biol. 1992;61(4):489-499.
19. Down JD, Boudewijn A, van Os R, Thames HD, Ploemacher RE. Variations in radiation sensitivity and repair among different hematopoietic stem cell subsets following fractionated irradiation. Blood. 1995;86(1): 122-127.
20. Down JD, Tarbell NJ, Thames HD, Mauch PM. Syngeneic and allogeneic bone marrow engraftment after total body irradiation: dependence on dose, dose rate, and fractionation. Blood. 1991;77(3):661-669.
21. van Os R, Thames HD, Konings AW, Down JD. Radiation dose-fractionation and dose-rate relationships for long-term repopulating hemopoietic stem cells in a murine bone marrow transplant model. Radiat Res. 1993;136(1): 118-125. (Pubitemid 23342608)
22. Neta R, Oppenheim JJ, Douches S. Interdependence of the radioprotective effects of human recombinant interleukin 1 alpha, tumor necrosis factor alpha, granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony-stimulating factor. J Immunol. 1988;140(1):108-111. (Pubitemid 18050689)
23. Slørdal L, Muench MO, Warren DJ, Moore MA. Radioprotection by murine and human tumornecrosis factor: dose-dependent effects on hematopoiesis in the mouse. Eur J Haematol. 1989;43(5):428-434. (Pubitemid 20088280)
24. Moreb J, Zucali JR. The therapeutic potential of interleukin-1 and tumor necrosis factor on hematopoietic stem cells. Leuk Lymphoma. 1992;8(4-5):267-275. (Pubitemid 23035514)
25. Pearl-Yafe M, Yolcu ES, Stein J, et al. Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis. Exp Hematol. 2007;35(10):1601-1612. (Pubitemid 47419142)
26. Mizrahi K, Stein J, Pearl-Yafe M, Kaplan O, Yaniv I, Askenasy N. Regulatory functions of TRAIL in hematopoietic progenitors: human umbilical cord blood and murine bone marrow transplantation. Leukemia. 2010;24(7): 1325-1334.
27. Pearl-Yafe M, Mizrahi K, Stein J, et al. Tumor necrosis factor receptors support murine hematopoietic progenitor function in the early stages of engraftment. Stem Cells. 2010;28(7): 1270-1280.
28. Askenasy N, Yolcu ES, Yaniv I, Shirwan H. Induction of tolerance using Fas-ligand: a double-edged immunomodulator. Blood. 2005; 105(4):1396-1404. (Pubitemid 40223653)
29. Mizrahi K, Kagan S, Stein J, Yaniv I, Zipori D, Askenasy N. Resistance of hematopoietic progenitors to Fas-mediated apoptosis is actively sustained by NFκB with a characteristic transcriptional signature. Stem Cells Dev. 2014; 23(6):676-686.
30. Majka M, Janowska-Wieczorek A, Ratajczak J, et al. Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood. 2001;97(10):3075-3085.
31. Askenasy N, Yolcu ES, Shirwan H, Stein J, Yaniv I, Farkas DL. Characterization of adhesion and viability of early seeding hematopoietic cells in the host bone marrow in vivo and in situ. Exp Hematol. 2003;31(12):1292-1300. (Pubitemid 37510035)
32. Pearl-Yafe M, Stein J, Yolcu ES, et al. Fas transduces dual apoptotic and trophic signals in hematopoietic progenitors. Stem Cells. 2007; 25(12):3194-3203. (Pubitemid 350294445)
33. Mizrahi K, Ash S, Peled T, Yaniv I, Stein J, Askenasy N. Negative selection by apoptosis enriches progenitors in naïve and expanded human umbilical cord blood grafts. Bone Marrow Transplant. 2014. (in press).
34. Mizrahi K, Yaniv I, Ash S, Stein J, Askenasy N. Apoptotic signaling through Fas and TNF receptors ameliorates GVHD in mobilized peripheral blood grafts. Bone Marrow Transplant. 2014;49(5):640-648.
35. Tao W, Hangoc G, Hawes JW, Si Y, Cooper S, Broxmeyer HE. Profiling of differentially expressed apoptosis-related genes by cDNA arrays in human cord blood CD34+ cells treated with etoposide. Exp Hematol. 2003;31(3): 251-260. (Pubitemid 36313268)
36. Ng YY, van Kessel B, Lokhorst HM, et al. Gene-expression profiling of CD34+ cells from various hematopoietic stem-cell sources reveals functional differences in stem-cell activity. J Leukoc Biol. 2004;75(2):314-323. (Pubitemid 38174589)
37. Jaatinen T, Hemmoranta H, Hautaniemi S, et al. Global gene expression profile of human cord blood-derived CD133+ cells. Stem Cells. 2006; 24(3):631-641. (Pubitemid 44464767)
38. Panepucci RA, Calado RT, Rocha V, Proto-Siqueira R, Silva WA Jr, Zago MA. Higher expression of transcription targets and components of the nuclear factor-kappaB pathway is a distinctive feature of umbilical cord blood CD34+ precursors. Stem Cells. 2007; 25(1):189-196. (Pubitemid 46052990)
39. Peters R, Leyvraz S, Perey L. Apoptotic regulation in primitive hematopoietic precursors. Blood. 1998;92(6):2041-2052. (Pubitemid 28446694)
40. Domen J, Cheshier SH, Weissman IL. The role of apoptosis in the regulation of hematopoietic stem cells: Overexpression of Bcl-2 increases both their number and repopulation potential. J Exp Med. 2000;191(2):253-264.
41. Bárcena A, Park SW, Banapour B, Muench MO, Mechetner E. Expression of Fas/CD95 and Bcl-2 by primitive hematopoietic progenitors freshly isolated from human fetal liver. Blood. 1996; 88(6):2013-2025. (Pubitemid 26307903)
42. Maurillo L, Del Poeta G, Venditti A, et al. Quantitative analysis of Fas and bcl-2 expression in hematopoietic precursors. Haematologica. 2001;86(3):237-243. (Pubitemid 32291060)
43. Kim H, Whartenby KA, Georgantas RW III, Wingard J, Civin CI. Human CD34+ hematopoietic stem/progenitor cells express high levels of FLIP and are resistant to Fas-mediated apoptosis. Stem Cells. 2002; 20(2):174-182. (Pubitemid 34297265)
44. Ratajczak J, Kucia M, Reca R, Zhang J, Machalinski B, Ratajczak MZ. Quiescent CD34+ early erythroid progenitors are resistant to several erythropoietic 'inhibitory' cytokines; role of FLIP. Br J Haematol. 2003;123(1):160-169. (Pubitemid 37222775)
45. Fukuda S, Pelus LM. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood. 2001;98(7):2091-2100.
46. Pyatt DW, Stillman WS, Yang Y, Gross S, Zheng JH, Irons RD. An essential role for NF-kappaB in human CD34(+) bone marrow cell survival. Blood. 1999;93(10):3302-3308. (Pubitemid 29220897)
47. Kerzic PJ, Pyatt DW, Zheng JH, Gross SA, Le A, Irons RD. Inhibition of NF-kappaB by hydroquinone sensitizes human bone marrow progenitor cells to TNF-alpha-induced apoptosis. Toxicology. 2003;187(2-3):127-137. (Pubitemid 36423308)
48. Bugarski D, Krstic A, Mojsilovic S, et al. Signaling pathways implicated in hematopoietic progenitor cell proliferation and differentiation. Exp Biol Med (Maywood). 2007;232(1):156-163. [Maywood]. (Pubitemid 46089950)
49. De Molfetta GA, Lucíola Zanette D, Alexandre Panepucci R, Dos Santos AR, da Silva WA Jr, Antonio Zago M. Role of NFKB2 on the early myeloid differentiation of CD34+ hematopoietic stem/progenitor cells. Differentiation. 2010;80(4-5):195-203.
50. Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation. Nat Rev Immunol. 2008;8(11):837-848.
51. Zipori D. The stem state: plasticity is essential, whereas self-renewal and hierarchy are optional. Stem Cells. 2005;23(6):719-726. (Pubitemid 40791787)
52. Askenasy N, Yaniv I, Stein J, Sharkis SJ. Our perception of developmental plasticity: esse est percipi (to be is to be perceived)? Curr Stem Cell Res Ther. 2006;1(1):85-94.
53. Shoshani O, Zipori D. Mammalian cell dedifferentiation as a possible outcome of stress. Stem Cell Rev. 2011;7(3):488-493.
54. Mizrahi K, Stein J, Yaniv I, Kaplan O, Askenasy N. TNF-α has tropic rather than apoptotic activity in human hematopoietic progenitors: involvement of TNF receptor-1 and caspase-8. Stem Cells. 2013;31(1):156-166.
55. Trumpp A, Essers M, Wilson A. Awakening dormant haematopoietic stem cells. Nat Rev Immunol. 2010;10(3):201-209.
56. Song JH, Bellail A, Tse MC, Yong VW, Hao C. Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. J Neurosci. 2006;26(12):3299-3308.
57. Haase G, Pettmann B, Raoul C, Henderson CE. Signaling by death receptors in the nervous system. Curr Opin Neurobiol. 2008;18(3): 284-291.
58. Harry GJ, Lefebvre d'Hellencourt C, McPherson CA, Funk JA, Aoyama M, Wine RN. Tumor necrosis factor p55 and p75 receptors are involved in chemical-induced apoptosis of dentate granule neurons. J Neurochem. 2008; 106(1):281-298. (Pubitemid 351840211)
59. Lambert C, Landau AM, Desbarats J. Fasbeyond death: a regenerative role for Fas in the nervous system. Apoptosis. 2003;8(6):551-562. (Pubitemid 37411739)
60. Kajiwara K, Ogata S, Tanihara M. Promotion of neurite outgrowth from fetal hippocampal cells by TNF-alpha receptor 1-derived peptide. Cell Transplant. 2005;14(9):665-672. (Pubitemid 43053757)
61. Desbarats J, Newell MK. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med. 2000;6(8):920-923. (Pubitemid 30644752)
62. Jacobsen SE, Ruscetti FW, Dubois CM, Keller JR. Tumor necrosis factor alpha directly and indirectly regulates hematopoietic progenitor cell proliferation: role of colony-stimulating factor receptor modulation. J Exp Med. 1992;175(6): 1759-1772.
63. Secchiero P, Gonelli A, Mirandola P, et al. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood. 2002;100(7): 2421-2429.
64. Mizrahi K, Askenasy N. Activation and crosstalk between TNF family receptors in umbilical cord blood cells is not responsible for loss of engraftment capacity following culture. Am J Stem Cells. 2013;2(3):155-164.
65. Bárcena A, Muench MO, Song KS, Ohkubo T, Harrison MR. Role of CD95/Fas and its ligand in the regulation of the growth of human CD34(++) CD38(-) fetal liver cells. Exp Hematol. 1999; 27(9):1428-1439. (Pubitemid 29409462)
66. Josefsen D, Myklebust JH, Lynch DH, Stokke T, Blomhoff HK, Smeland EB. Fas ligand promotes cell survival of immature human bone marrow CD34+CD38- hematopoietic progenitor cells by suppressing apoptosis. Exp Hematol. 1999; 27(9):1451-1459. (Pubitemid 29409464)
67. Warren DJ, Slørdal L, Moore MA. Tumornecrosis factor induces cell cycle arrest in multipotential hematopoietic stem cells: a possible radioprotective mechanism. Eur J Haematol. 1990;45(3):158-163. (Pubitemid 20358754)
68. Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995;83(5): 793-802.
69. Müller S, Rihs S, Schneider JM, et al. Soluble TNF-alpha but not transmembrane TNF-alpha sensitizes T cells for enhanced activation-induced cell death. Eur J Immunol. 2009;39(11): 3171-3180.
70. Stahnke K, Hecker S, Kohne E, Debatin KM. CD95 (APO-1/FAS)-mediated apoptosis in cytokine-activated hematopoietic cells. Exp Hematol. 1998;26(9):844-850. (Pubitemid 28350755)
71. Dybedal I, Yang L, Bryder D, Aastrand-Grundstrom I, Leandersson K, Jacobsen SE. Human reconstituting hematopoietic stem cells up-regulate Fas expression upon active cell cycling but remain resistant to Fas-induced suppression. Blood. 2003;102(1):118-126. (Pubitemid 36759644)
72. Takizawa H, Boettcher S, Manz MG. Demand-adapted regulation of early hematopoiesis in infection and inflammation. Blood. 2012;119(13): 2991-3002.
73. Cheers C, Haigh AM, Kelso A, Metcalf D, Stanley ER, Young AM. Production of colony-stimulating factors (CSFs) during infection: separate determinations of macrophage-, granulocyte-, granulocyte-macrophage-, and multi-CSFs. Infect Immun. 1988;56(1):247-251. (Pubitemid 18032159)
74. Nagai Y, Garrett KP, Ohta S, et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity. 2006;24(6):801-812. (Pubitemid 43867369)
75. Gardner RV. Interferon-gamma (IFN-gamma) as a potential radio- and chemo-protectant. Am J Hematol. 1998;58(3):218-223. (Pubitemid 28303551)
76. Yu JM, Emmons RV, Hanazono Y, Sellers S, Young NS, Dunbar CE. Expression of interferongamma by stromal cells inhibits murine long-term repopulating hematopoietic stem cell activity. Exp Hematol. 1999;27(5):895-903. (Pubitemid 29231028)
77. Hoffmann A, Levchenko A, Scott ML, Baltimore D. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science. 2002;298(5596):1241-1245. (Pubitemid 35285493)
78. Nelson DE, Ihekwaba AE, Elliott M, et al. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science. 2004; 306(5696):704-708. (Pubitemid 39440922)
79. Pearl-Yafe M, Yolcu ES, Stein J, et al. Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and nonimmunogenic interactions. Stem Cells. 2007;25(6):1448-1455. (Pubitemid 47106012)
80. Pronk CJ, Veiby OP, Bryder D, Jacobsen SE. Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors. J Exp Med. 2011;208(8): 1563-1570.
81. Rebel VI, Hartnett S, Hill GR, Lazo-Kallanian SB, Ferrara JL, Sieff CA. Essential role for the p55 tumor necrosis factor receptor in regulating hematopoiesis at a stem cell level. J Exp Med. 1999;190(10):1493-1504.
82. Lardon F, Snoeck HW, Berneman ZN, et al. Generation of dendritic cells from bone marrow progenitors using GM-CSF, TNF-alpha, and additional cytokines: antagonistic effects of IL-4 and IFN-gamma and selective involvement of TNF-alpha receptor-1. Immunology. 1997;91(4): 553-559. (Pubitemid 27312337)
83. Rezzoug F, Huang Y, Tanner MK, et al. TNF-alpha is critical to facilitate hemopoietic stem cell engraftment and function. J Immunol. 2008;180(1):49-57.
84. Umland O, Heine H, Miehe M, Marienfeld K, Staubach KH, Ulmer AJ. Induction of various immune modulatory molecules in CD34(+) hematopoietic cells. J Leukoc Biol. 2004;75(4): 671-679. (Pubitemid 38405659)
85. Whartenby KA, Straley EE, Kim H, et al. Transduction of donor hematopoietic stemprogenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation. Blood. 2002; 100(9):3147-3154. (Pubitemid 35217062)
86. Jones RJ, Collector MI, Barber JP, et al. Characterization of mouse lymphohematopoietic stem cells lacking spleen colony-forming activity. Blood. 1996;88(2):487-491. (Pubitemid 26240380)
87. Jang YY, Sharkis SJ. Stem cell plasticity: a rare cell, not a rare event. Stem Cell Rev. 2005; 1(1):45-51. (Pubitemid 41003463)
88. Rachamim N, Gan J, Segall H, et al. Tolerance induction by "megadose" hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host antidonor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation. 1998;65(10):1386-1393.
89. + progenitor cells: evidence for a deletion-based mechanism mediated by TNF-alpha. Blood. 2005;105(6): 2585-2593.
90. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol. 2006;6(2):93-106. (Pubitemid 43361585)
91. Askenasy N, Farkas DL. Antigen barriers or available space do not restrict in situ adhesion of hemopoietic cells to bone marrow stroma. Stem Cells. 2002;20(1):80-85. (Pubitemid 34118913)
92. Lepri E, Delfino DV, Migliorati G, Moraca R, Ayroldi E, Riccardi C. Functional expression of Fas on mouse bone marrow stromal cells: upregulation by tumor necrosis factor-alpha and interferon-gamma. Exp Hematol. 1998;26(13): 1202-1208. (Pubitemid 28541762)
93. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12(6):443-458.
94. Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001;98(12): 3192-3204.
95. Askenasy N, Mizrahi K, Ash S, Askenasy EM, Yaniv I, Stein J. Depletion of naïve lymphocytes with fas ligand ex vivo prevents graft-versus-host disease without impairing T cell support of engraftment or graft-versus-tumor activity. Biol Blood Marrow Transplant. 2013;19(2):185-195.
96. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008;19(3-4):325-331.
97. Droin N, Guéry L, Benikhlef N, Solary E. Targeting apoptosis proteins in hematological malignancies. Cancer Lett. 2013;332(2): 325-334.
98. Qin Y, Camoretti-Mercado B, Blokh L, Long CG, Ko FD, Hamann KJ. Fas resistance of leukemic eosinophils is due to activation of NF-kappa B by Fas ligation. J Immunol. 2002;169(7):3536-3544.
99. de Totero D, Montera M, Rosso O, et al. Resistance to CD95-mediated apoptosis of CD40-activated chronic lymphocytic leukemia B cells is not related to lack of DISC molecules expression. Hematol J. 2004;5(2):152-160. (Pubitemid 38519265)
100. Romano C, De Fanis U, Sellitto A, et al. Induction of CD95 upregulation does not render chronic lymphocytic leukemia B-cells susceptible to CD95-mediated apoptosis. Immunol Lett. 2005;97(1):131-139. (Pubitemid 40038864)
101. Choi SW, Stiff P, Cooke K, et al. TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes. Biol Blood Marrow Transplant. 2012;18(10): 1525-1532.
102. Alousi AM, Weisdorf DJ, Logan BR, et al; Blood and Marrow Transplant Clinical Trials Network. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009; 114(3):511-517.
103. Welsh JP, Rutherford TR, Flynn J, Foukaneli T, Gordon-Smith EC, Gibson FM. In vitro effects of interferon-gamma and tumor necrosis factor-alpha on CD34+ bone marrow progenitor cells from aplastic anemia patients and normal donors. Hematol J. 2004;5(1):39-46. (Pubitemid 38262789)
104. Zeng W, Miyazato A, Chen G, Kajigaya S, Young NS, Maciejewski JP. Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood. 2006;107(1): 167-175. (Pubitemid 43053539)
105. Kakagianni T, Giannakoulas NC, Thanopoulou E, et al. A probable role for trail-induced apoptosis in the pathogenesis of marrow failure. Implications from an in vitro model and from marrow of aplastic anemia patients. Leuk Res. 2006;30(6):713-721.
106. Platzbecker U, Kurre P, Guardiola P, et al. Fanconi anemia type C-deficient hematopoietic cells are resistant to TRAIL (TNF-related apoptosis-inducing ligand)-induced cleavage of pro-caspase-8. Exp Hematol. 2004;32(9): 815-821. (Pubitemid 39166027)
107. Milsom MD, Schiedlmeier B, Bailey J, et al. Ectopic HOXB4 overcomes the inhibitory effect of tumor necrosis factor-alpha on Fanconi anemia hematopoietic stem and progenitor cells. Blood. 2009;113(21):5111-5120.